D. Boral Capital Reaffirms “Buy” Rating for Plus Therapeutics (NASDAQ:PSTV)

Plus Therapeutics (NASDAQ:PSTV)‘s stock had its “buy” rating reissued by stock analysts at D. Boral Capital in a report released on Friday,Benzinga reports. They currently have a $9.00 price target on the stock. D. Boral Capital’s price objective would indicate a potential upside of 492.11% from the company’s current price.

PSTV has been the subject of a number of other reports. HC Wainwright cut their price target on Plus Therapeutics from $8.00 to $5.50 and set a “buy” rating for the company in a report on Friday. Ascendiant Capital Markets cut their target price on shares of Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a research note on Monday, December 9th.

Plus Therapeutics Price Performance

Shares of Plus Therapeutics stock opened at $1.52 on Friday. Plus Therapeutics has a 1 year low of $0.24 and a 1 year high of $2.67. The business has a 50 day moving average price of $1.11 and a 200 day moving average price of $1.24. The company has a market capitalization of $8.96 million, a P/E ratio of -0.60 and a beta of 0.73.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.